Anish John - Jun 1, 2022 Form 4 Insider Report for Oncocyte Corp (OCX)

Role
SVP, Finance, and Interim CFO
Signature
/s/ Anish John
Stock symbol
OCX
Transactions as of
Jun 1, 2022
Transactions value $
$0
Form type
4
Date filed
6/15/2022, 07:49 PM
Next filing
Aug 17, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OCX Option to Purchase Common Stock Award $0 +50K $0.00 50K Jun 1, 2022 Common Stock 50K $0.99 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the options will become exercisable after one year of continuous service from the effective date of grant, and the balance will become exercisable in 36 equal monthly installments commencing one year after the date of grant subject to continuous service through the applicable vesting date.